Kyntra Bio, Inc. KYNB NASDAQ · Healthcare · United States
$1.56 -14.75% -$0.27
Summary
33 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 658 USD is left as net profit.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 64% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 0.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 48% a year over 5 years. Over the last 3 years it fell by 64% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 80 USD
- Research and development 564 USD
- Sales and administration 555 USD
- Taxes and other -1,758 USD
- Net profit 658 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 658 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 8
- Sell 2
Today's price within the analysts' price targets
The average target of $28 is 1,695% above today's price. 33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Drug Product Revenue 100%
By region
- Europe 88%
- JAPAN 12%
Drug Product Revenue brings in 100% of revenue.
Segments in detail